drugset / Trial / NCT07289503
Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above
Phase 1
Active not recruiting
96 enrolled
Suzhou Abogen Biosciences Co., Ltd.
Abogen Biosciences (Shanghai) Co., Ltd · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of a single injection of three dose levels of ABO1105 in adults aged 18 years or above.
Timeline
- Start
- 2025-05-27
- Primary completion
- 2025-09-04
- Completion
- 2026-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABO1105 | Unknown | — | — |